Back to top

Piper Sandler Remains a Buy on Madrigal Pharmaceuticals (MDGL)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Madrigal Pharmaceuticals today and set a price target of $900.00. Rahimi covers the...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Madrigal Pharmaceuticals, Inc. (MDGL)